In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically

Jrhau Lung, Kuan Liang Chen, Chien Hui Hung, Chih Cheng Chen, Ming Szu Hung, Yu Ching Lin, Ching Yuan Wu, Kuan Der Lee, Neng Yao Shih, Ying Huang Tsai

研究成果: 雜誌貢獻文章同行評審

8 引文 斯高帕斯(Scopus)


Unlimited growth of cancer cells requires an extensive nutrient supply. To meet this demand, cancer cells drastically upregulate glucose uptake and metabolism compared to normal cells. This difference has made the blocking of glycolysis a fascinating strategy to treat this malignant disease. α-enolase is not only one of the most upregulated glycolytic enzymes in cancer cells, but also associates with many cellular processes or conditions important to cancer cell survival, such as cell migration, invasion, and hypoxia. Targeting α-enolase could simultaneously disturb cancer cells in multiple ways and, therefore, is a good target for anticancer drug development. In the current study, more than 22 million chemical structures meeting the criteria of Lipinski’s rule of five from the ZINC database were docked to α-enolase by virtual screening. Twenty-four chemical structures with docking scores better than that of the enolase substrate, 2-phosphoglycerate, were further screened by the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties prediction. Four of them were classified as non-mutagenic, non-carcinogenic, and capable of oral administration where they showed steady interactions to α-enolase that were comparable, even superior, to the currently available inhibitors in molecular dynamics (MD) simulation. These compounds may be considered promising leads for further development of the α-enolase inhibitors and could help fight cancer metabolically.
頁(從 - 到)3281-3290
期刊Drug Design, Development and Therapy
出版狀態已發佈 - 11月 16 2017

ASJC Scopus subject areas

  • 藥理
  • 藥學科學
  • 藥物發現


深入研究「In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically」主題。共同形成了獨特的指紋。